Valuation
- Market cap
- 963,000
- Revenue TTM
- $0
- Net income TTM
- $-12,520,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 43,700
- Avg volume
- 2,748,464
- Day's range
- $1.46 – $1.52
- Shares out
- 655,000
- Stochastic %K
- 1%
- Beta
- 0.65
- Analysts
- Sell
- Price target
- $3.00
Company profile
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverages machine learning an...
Show more
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting various unmet medical needs. It focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Houston, Texas.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 713 913 5608
- Website
- https://decoytx.com
- Address
- 2450 Holcombe Blvd, Suite X, Houston, United States
Latest news
No headlines yet.
